Showing cumulative cases — not day-to-day trends — could nudge people to avoid reckless behavior
In connection with funding, typically; those chasing money abroad tend to raise a lot more of it
The shift lends credibility to medicines vs. trials that exclude people 65 and older
New product filings to FDA included stronger safety features and larger technological advances
Companies with Chinese suppliers suffered — those with more diversified supply chains suffered more
Building adaptability into an approach improves performance
In LA, doctors who lose a patient to opioid overdose get a letter from the coroner; tweaking that letter had a substantial impact
Paperwork issues at physical therapy providers curtail care more often for minority and low-income patients
What emerges is a fragmented view of corporate contribution to global warming
The ethics of asking brain surgery patients to allow unrelated research while on the operating table
Advice for researchers aims to help improve both data collection and its interpretation
The most lucrative career paths avoid young, small firms
Because they’re harder to get, we assume they’re more potent — and thus preferable over legal ones.
Consumers, on the other hand, gained in good times and bad
Managing earnings at the cost of privacy
Can’t sell it, can’t borrow against it, can’t develop it